Overture Life Raises $20.6M for Advancing Embryology Lab Procedures
Investors such as Overwater Ventures, GV, and Khosla Ventures have contributed to Overture Life’s recent funding round, totaling $20.6M. The company aims to enhance fertility access by optimizing in vitro fertilization (IVF) labs for improved reproducibility, efficiency, and cost-effectiveness.
Under the leadership of CEO Hans Gangeskar, Overture Life merges engineering, reproductive medicine, and regulatory-grade validation to revolutionize embryology lab processes, focusing on egg freezing and embryo handling. By reducing the need for repeated cycles, increasing throughput, and lowering overall IVF costs, the company’s DaVitri platform integrates robotics, analytics, and clinical precision to empower clinics and patients worldwide.
In addition to its operations in the United States, Overture Life has a research and development center in Spain and a CLIA-licensed laboratory for non-invasive embryo selection. The company’s m|z, an AI-powered metabolomic test for embryo selection, has recently obtained CLIA certification in the U.S.
This funding round brings Overture Life’s total raised amount to $57M, supporting its mission to provide women and families with greater control over their fertility journeys.
FinSMEs
25/04/2025
